Locally Advanced Lung Non-Small Cell Carcinoma Clinical Trials

7 recruiting

Locally Advanced Lung Non-Small Cell Carcinoma Trials at a Glance

7 actively recruiting trials for locally advanced lung non-small cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Columbus, New Brunswick, and Cleveland. Lead sponsors running locally advanced lung non-small cell carcinoma studies include M.D. Anderson Cancer Center, Mayo Clinic, and Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

Browse locally advanced lung non-small cell carcinoma trials by phase

Treatments under study

About Locally Advanced Lung Non-Small Cell Carcinoma Clinical Trials

Looking for clinical trials for Locally Advanced Lung Non-Small Cell Carcinoma? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Lung Non-Small Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Lung Non-Small Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)37 enrolled9 locationsNCT07012031
Recruiting
Phase 3

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8
NRG Oncology474 enrolled471 locationsNCT05624996
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Not Applicable

Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation

Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+2 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT05010109
Recruiting
Not Applicable

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+10 more
Rutgers, The State University of New Jersey34 enrolled2 locationsNCT04751747
Recruiting
Phase 1

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+6 more
Ohio State University Comprehensive Cancer Center28 enrolled2 locationsNCT05136846
Recruiting

Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)

Locally Advanced Lung Non-Small Cell Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano150 enrolled1 locationNCT06361784